Show simple item record

dc.contributor.authorMcNamara, S
dc.contributor.authorStokes, S
dc.contributor.authorKilduff, R
dc.contributor.authorShine, A
dc.date.accessioned2016-02-24T14:49:35Zen
dc.date.available2016-02-24T14:49:35Zen
dc.date.issued2015-12en
dc.identifier.urihttp://hdl.handle.net/10147/597129en
dc.descriptionPregabalin (Lyricafi) is used in treating epilepsy, nerve pain and anxiety. Pregabalin was initially thought to have a low misuse potential however there are emerging reports of Pregabalin being abused. A study was commenced at the National Drug Treatment Centreâ s (NDTC) Drug Analysis Laboratory to determine the level of usage of Pregabalin within the addiction services population in Ireland. A total of 498 urine samples representing samples from 440 individual opioid substitution patients, initially screened by immunoassay for drugs of abuse, were subjected to further analysis for Pregabalin by Liquid Chromatography/Mass Spectrometry (LC/MS). Of 440 patients tested, 39 tested positive for Pregabalin (9.2%). Only 10 patients from this group were prescribed this drug to our knowledge thus giving an estimated rate of misuse of 7.0%. Other drugs detected in the Pregabalin positive patients were Opiates (31.8%), Cocaine (11.4%), Benzodiazepines (79.5%) and Cannabis (77.8%). Our study confirms that Pregabalin abuse is taking place amongst the addiction services population. We believe that misuse of this prescription drug is a serious emerging issue which should be monitored carefullyen
dc.language.isoenen
dc.publisherIrish Medical Journalen
dc.subjectDRUGSen
dc.subjectDRUGS MISUSEen
dc.subjectEPILEPSYen
dc.titlePregabalin abuse amongst opioid substitution treatment patientsen
dc.typeArticleen
dc.identifier.journalIrish Medical Journalen
refterms.dateFOA2018-08-27T12:41:15Z


Files in this item

Thumbnail
Name:
Article8340.pdf
Size:
5.854Kb
Format:
PDF
Description:
Main Article

This item appears in the following Collection(s)

Show simple item record